Symp 6

Title Poster First Author Abstract or summary Type
Efficacy of Risperidone Long-Acting injection in the first year of Schizophrenia: Relapse prevention and symptom reduction Kenneth Subotnik

Not Available

Conference Presentations
Long-acting injectable medication maintenance treatment of “first-episode” schizophrenia – a randomized effectiveness study Peter Weiden

Background: Because long-acting injectable (LAI) antipsychotics are largely reserved for persistently ill patients, little is known about the use of LAIs for “first-episode” outpatients. Methods: A prospective randomized controlled trial (RCT) between 12/2004 and 3/2007 of “first-episode” DSM-IV schizophreniform, schizophrenia, or schizoaffective disorder treated in an urban, public mental health service. Subjects were randomized at a 2:1 ratio to recommendation of LAI risperidone microspheres (RLAI) (n = 26) or continuation oral antipsychotic (ORAL) (n = 11), for up to 104 weeks.

Conference Presentations
The impact of long-acting injectable vs. oral risperidone on cognition and work functioning after an initial psychotic episode: the critical role of early medication adherence Keith Nuechterlein

Background: Cognitive deficits are a critical target for attempts to improve everyday functioning in schizophrenia. Although most studies have shown only modest effects of second-generation antipsychotic medications on cognitive deficits, they have typically focused on chronic phases of schizophrenia without considering medication adherence. Method: A 12-month, open-label, randomized controlled trial of long-acting injectable risperidone (RLAI) vs. oral risperidone is focusing on the impact of medication adherence after an initial episode of schizophrenia.

Conference Presentations